166 related articles for article (PubMed ID: 32910646)
1. Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.
Futatsugi K; Smith AC; Tu M; Raymer B; Ahn K; Coffey SB; Dowling MS; Fernando DP; Gutierrez JA; Huard K; Jasti J; Kalgutkar AS; Knafels JD; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Ryder T; Shavnya A; Stock IA; Tsai AS; Tesz GJ; Thuma BA; Weng Y; Wisniewska HM; Xing G; Zhou J; Magee TV
J Med Chem; 2020 Nov; 63(22):13546-13560. PubMed ID: 32910646
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease.
Zhu G; Li J; Lin X; Zhang Z; Hu T; Huo S; Li Y
J Med Chem; 2023 Oct; 66(19):13501-13515. PubMed ID: 37766386
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).
Huard K; Ahn K; Amor P; Beebe DA; Borzilleri KA; Chrunyk BA; Coffey SB; Cong Y; Conn EL; Culp JS; Dowling MS; Gorgoglione MF; Gutierrez JA; Knafels JD; Lachapelle EA; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Raymer B; Ross TT; Shavnya A; Smith AC; Subashi TA; Tesz GJ; Thuma BA; Tu M; Weaver JD; Weng Y; Withka JM; Xing G; Magee TV
J Med Chem; 2017 Sep; 60(18):7835-7849. PubMed ID: 28853885
[TBL] [Abstract][Full Text] [Related]
5. A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes.
Park SH; Helsley RN; Noetzli L; Tu HC; Wallenius K; O'Mahony G; Boucher J; Liu J; Softic S
STAR Protoc; 2021 Sep; 2(3):100731. PubMed ID: 34409309
[TBL] [Abstract][Full Text] [Related]
6. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects.
Miller CO; Yang X; Lu K; Cao J; Herath K; Rosahl TW; Askew R; Pavlovic G; Zhou G; Li C; Akiyama TE
Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E386-E393. PubMed ID: 29870677
[TBL] [Abstract][Full Text] [Related]
7. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.
Helsley RN; Park SH; Vekaria HJ; Sullivan PG; Conroy LR; Sun RC; Romero MDM; Herrero L; Bons J; King CD; Rose J; Meyer JG; Schilling B; Kahn CR; Softic S
J Hepatol; 2023 Jul; 79(1):25-42. PubMed ID: 36822479
[TBL] [Abstract][Full Text] [Related]
8. Michaelis-like complex of mouse ketohexokinase isoform C.
Gasper WC; Gardner S; Ross A; Oppelt SA; Allen KN; Tolan DR
Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):377-385. PubMed ID: 38805243
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.
Maryanoff BE; O'Neill JC; McComsey DF; Yabut SC; Luci DK; Gibbs AC; Connelly MA
Bioorg Med Chem Lett; 2012 Aug; 22(16):5326-9. PubMed ID: 22795331
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Birnbaum MJ; Calle RA
Med; 2021 Jul; 2(7):800-813.e3. PubMed ID: 35590219
[TBL] [Abstract][Full Text] [Related]
11. Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
Metabolism; 2023 Aug; 145():155591. PubMed ID: 37230214
[TBL] [Abstract][Full Text] [Related]
12. Structures of alternatively spliced isoforms of human ketohexokinase.
Trinh CH; Asipu A; Bonthron DT; Phillips SE
Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):201-11. PubMed ID: 19237742
[TBL] [Abstract][Full Text] [Related]
13. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver.
Lanaspa MA; Sanchez-Lozada LG; Cicerchi C; Li N; Roncal-Jimenez CA; Ishimoto T; Le M; Garcia GE; Thomas JB; Rivard CJ; Andres-Hernando A; Hunter B; Schreiner G; Rodriguez-Iturbe B; Sautin YY; Johnson RJ
PLoS One; 2012; 7(10):e47948. PubMed ID: 23112875
[TBL] [Abstract][Full Text] [Related]
14. Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice.
Lanaspa MA; Andres-Hernando A; Orlicky DJ; Cicerchi C; Jang C; Li N; Milagres T; Kuwabara M; Wempe MF; Rabinowitz JD; Johnson RJ; Tolan DR
J Clin Invest; 2018 Jun; 128(6):2226-2238. PubMed ID: 29533924
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin resistance and proinflammatory changes in the visceral adipose tissue induced by fructose consumption via ketohexokinase-dependent pathway.
Marek G; Pannu V; Shanmugham P; Pancione B; Mascia D; Crosson S; Ishimoto T; Sautin YY
Diabetes; 2015 Feb; 64(2):508-18. PubMed ID: 25187370
[TBL] [Abstract][Full Text] [Related]
16. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
Ouyang X; Cirillo P; Sautin Y; McCall S; Bruchette JL; Diehl AM; Johnson RJ; Abdelmalek MF
J Hepatol; 2008 Jun; 48(6):993-9. PubMed ID: 18395287
[TBL] [Abstract][Full Text] [Related]
17. Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells.
Ma G; Liu S; Cai F; Liang H; Deng J; Zhang R; Cai M
Exp Cell Res; 2024 May; 438(1):114038. PubMed ID: 38614422
[TBL] [Abstract][Full Text] [Related]
18. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease.
Mirtschink P; Krishnan J; Grimm F; Sarre A; Hörl M; Kayikci M; Fankhauser N; Christinat Y; Cortijo C; Feehan O; Vukolic A; Sossalla S; Stehr SN; Ule J; Zamboni N; Pedrazzini T; Krek W
Nature; 2015 Jun; 522(7557):444-449. PubMed ID: 26083752
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
20. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells.
Cirillo P; Gersch MS; Mu W; Scherer PM; Kim KM; Gesualdo L; Henderson GN; Johnson RJ; Sautin YY
J Am Soc Nephrol; 2009 Mar; 20(3):545-53. PubMed ID: 19158351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
